Halting the autoimmune attack on beta cells by redirecting or dampening the immune system remains one of the foremost therapeutic goals in type 1 diabetes (T1D). Progress in the field has been slow due to important ethical considerations. Namely, side effects ... ...

请注册登录后继续浏览